Particularly, the immunotherapy targeting programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) is the latest treatment available for HCC patients (Balar and Weber, 2017). Here, PDCD1 is linked to hepatocellular carcinoma.